RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy

• DOI: 10.4161/cbt.13.4.18692
• Publication Date: 2012-02-21T16:51:08Z
• Authors: Shunrong Ji; Jin Xu; Bo Zhang; Wantong Yao; Wenyan Xu; Wenzhe Wu; Yongfeng Xu; Hao Wang; Quanxing Ni; Huimin Hou; Xianjun Yu
• Keywords: 0303 health sciences; Microscopy, Confocal; 3. Good health; Pancreatic Neoplasms; 03 medical and health sciences; Drug Delivery Systems; Microscopy, Fluorescence; Albumins; Cell Line, Tumor; Animals; Nanoparticles; Cattle; Oligopeptides

Integrin αvβ3 receptor is expressed on several types of cancer cells, including pancreatic and plays an important role in tumor growth metastasis. The ability to target the integrin cells increases efficacy targeted therapy reduces side effects. aim this study develop a novel arginine-glycine-aspartic acid (RGD) peptide-conjugated albumin nanoparticle enhance intracellular uptake anticancer drug into through receptor-mediated endocytosis. In cellular studies, fluorescent signal RGD-conjugated BSANPs BxPC3 was higher than that without RGD conjugation as determined by fluorescence spectrophotometer. We also found bound time- concentration-dependent manner. inhibited excess amount free peptide, indicating binding and/or were mediated receptor. Furthermore, nanoparticles be located close nuclei using laser scanning confocal microscopy. Besides, no significant vitro cytotoxicity observed measured with MTT assay. Both vivo antitumor improved targeting gemcitabine-loaded BxPC-3 peptides. Therefore, hold great potential effective delivery system deliver therapeutic agents cancer.